• About us
• Contact

Advertisement

Organisation › Details

LAB282 (BRIDGE collaboration of Univ Oxford + Evotec)

LAB282, initiated in November 2016, is a new £ 13 m partnership between the Oxford University, Oxford University Innovation Ltd, Oxford Sciences Innovation plc and Evotec AG created to identify and develop new approaches to treating serious diseases, which originate from the Oxford University. The goal is to accelerate the achievement of pre-clinical proof of concept for new drugs and to generate new spin-out companies. The name derived from the pantone colour code of "Oxford Blue". *

 

	Start	2016-11-10 established jv
	Group	University of Oxford
	Industry	drug discovery
	Industry 2	translational medicine / translational research
	Person	Hanke, Thomas (Evotec 202104 Head of Academic Partners joined 201311 before Novo Nordisk + TeGenero)
	Person 2	Porter, Carolyn (CytoSeek 202001– CEO before OxStem + Univ Oxford/Isis Innovation + Novartis + Chiron)
	Region	Oxford, Oxfordshire
	Country	United Kingdom (GB)
	City	n. a.
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«: Evotec AG. (2/21/17). "Press Release: »Lab282« Awarded First Projects. Oxford University and Evotec's Drug Discovery Partnership Launched Last November to Accelerate Drugs to Market Begins Making Awards". Hamburg.
		Record changed: 2023-07-10

Advertisement

More documents for University of Oxford

• [1] CEPI. (8/29/23). "Press Release: CEPI and University of Oxford to Accelerate Vaccine Development against Disease X". Oslo & Oxford....
• [2] Oxford Science Park, The. (7/18/22). "Press Release: The Oxford Science Park Agrees to Sale of Development Site to the Lawrence J. Ellison Institute for Transformative Medicine". Oxford....
• [3] Oxford Science Enterprises plc. (7/11/22). "Press Release: Oxford Science Enterprises Raises £250 Million"....
• [4] Oxford VR Ltd.. (4/7/22). "Press Release: OxfordVR Technology a World First Success in Automating Psychological Therapy Using Virtual Reality (VR)"....
• [5] Exscientia Ltd.. (8/4/21). "Press Release: Exscientia Builds Automated Laboratories in Oxford to Expand Pipeline"....
• [6] AstraZeneca plc. (12/30/20). "Press Release: AstraZeneca’s COVID-19 Vaccine Authorised for Emergency Supply in the UK"....
• [7] Enara Bio Ltd.. (12/9/20). "Press Release: Enara Bio Relocates to The Oxford Science Park’s Newest Facility to Expand R&D Capabilities in the Search for Novel Vancer Immunotherapies". Oxford & London....
• [8] Evotec SE. (9/2/20). "Press Release: Evotec Expands Its Proprietary Patient Database into Liver Disease with Unique Access to QUOD Biobank". Hamburg....
• [9] Halix B.V.. (4/15/20). "Press Release: Halix Enters Collaboration with the University of Oxford for GMP Manufacturing of a COVID-19 Vaccine". Leiden....
• [10] Oxford University Innovation. (1/23/20). "Press Release: Oxford Investment Opportunity Network and Oxford Angel Network Join Forces"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.